1. Project prepared and
presented by:
Jinia Biswas
Sruti Jain
Vibhav Kaushal

2. HISTORY
• 1983 – Sun Pharma established with five psychiatry
products and two person marketing team at Vapi, Gujarat.
• 1994 – Sun Pharma went public in an issue that was
oversubscribed 55 times.
• 1989 – Exports to neighbouring countries began.
• 2000 – Sun Pharma ranked 5th largest pharmaceutical
company in India.
• 2007 – Sun Pharma demerged into a separate entity Sun
Pharma Advanced Research Company, the first research
company to get listed on stock exchanges in India.
• 2012 – Major acuisitions in US completed.

3. BOARD OF DIRECTORS
Chairman – Israel Makov
Managing Director – Dilip S. Shanghvi
Executive Director – Sudhir V. Valia, Sailesh
Desai
Non-executive independent director –
Hasmukh Shah, Keki M. Mistry, Ashwin
Dani, S. Mohanchand Dadha.

4. AWARDS 2012
 Business Leadership Of The Year -
Pharmaceutical – NDTV Profit
 Most outstanding Company Of The Year –
CNBC TV 18 India Business Leader Award
 Listed on World’s 100 Most Innovative
Companies – Forbes
 Listed on Asia’s Fab 50 - Forbes

5. ACUISITIONS & JOINT VENTURES
Generic Business of URL Pharma , United
States
Dusa Pharmaceuticals Inc, United States
Joint Venture with MSD
Acquired Caraco Pharmaceutical Laboratories
Ltd
Acquired Taro Pharmaceutical Industries Ltd
Acquired Inwood Laboratories Incorprated

6. SHARE PRICE
As on 26th November, 2013 :
BSE Rs 587.55, 7.00(+1.21%) , Volume 17,147
As on 26th November, 2013 :
NSE Rs 587.70, 6.85(+1.18%), Volume
150,672

7. SUN PHARMA INDUSTRIES STOCK
PRICE
P/E 652.30 P/C(Based on standalone
numbers) 443.17
BOOK VALUE(Rs) 41.64 PRICE BOOK(Based on
standalone numbers) 13.94
DIVIDEND(%) 250.00% DIVIDEND YIELD(%) 0.43%
MARKET LOT 1 FACE VALUE(Rs) 1
INDUTSRY P/E 32.03 DELIVERABLES(%) 69.85

8. CONTRIBUTION TO SENSEX
COMPANY
NAME
INDUSTRY LAST
PRICE
CHANGE
Rs (%)
MARKET
CAPITALIZATION
(CRORES)
CONTRIBUT
ON
SUN PHARMA PHARMACEUTICAL 587.70 7.15 1.23 48688.92 8.56
CIPLA DO 390.75 3.45 0.89 20393.20 2.68
DR.REDDY’S
LAB
DO 2438.00 -1.30 -0.05 31102.74 -0.24

9. CONTRIBUTION TO NIFTY
COMPANY LAST PRICE CHANGE
Rs (%)
MARKET
CAP(CRORES)
CONTRIBUTION
SUN PHARMA 589.80 8.95 1.54 122,157.25 2.07
LUPIN 853.50 2.90 0.34 38251.99 0.15
CIPLA 390.60 3.50 0.90 31362.11 0.31
RANBAXY 428.00 3.05 0.72 18110.47 0.14
DR.REDDY’S
LAB
2446.80 6.65 0.27 41620 0.13

10. DIVIDEND HISTORY
Financial
Year
Interim/F
inal
Rate of
Dividend
Dividend
per
equity
share(Rs
Face
Value
Book
Closure
From To
Date of
declarati
of
dividend
2007-
2008
Final 210% 10.50 Rs 5 27/08/08 6/09/08 6/09/08
2008-
2009
Final 275% 13.75 Rs 5 25/08/09 5/09/09 11/09/09
2009-
2010
Final 275% 13.75 Rs 5 14/09/10 24/09/10 24/09/10
2010-
2011
Final 350% 3.50 Re 1 6/09/11 16/09/11 16/09/11
2011-
2012
Interim 425% 4.25 Re 1 16/08/12 Record
Date
10/18/12

13. TREND ANALYSIS

14. KEY PERFORMANCE INDICATORS
INDICATOR/
YEAR
TOTAL INCOME PROFIT FOR
THE YEAR
RESERVE &
SURPLUS
EARNINGS
PER SHARE
NET BLOCK
2008-2009 44808 18780 69414 87.8 14625
2009-2010 42123 13470 77254 65.2 15328
2010-2011 60827 18161 93798 17.5 25214
2011-2012 84910 26567 121322 25.7 29295
2012-2013 116880 29831 148862 28.8 45145

15. 21st ANNUAL REPORT FOR THE YEAR
ENDED MARCH 31, 2013
Particulars Year ended March
31,2013(Rs in
million)
Year ended March
31, 2012(Rs in
million)
Total Income 26,683 43,584
Profit After Tax 5,166 16,975
Dividend on Equity Shares 5,178 4,401
Corporate Dividend Tax 880 714
Transfer to various reserves 520 2,000
Amount of dividend per equity share
of Re 1 each
2.50 4.25
Book Value per equity share of Re 1
each
75 76

16. EXPENDITURE ON R & D Year ended March 31,
2013(Rs in million)
Year ended March 31,
2012(Rs in million)
Capital 377.2 352.1
Revenue 2725 1831.9
Total 3102.2 2184
Total R&D as a % of
Total Turnover
13.8% 9.1%

17. CURRENT NEWS ON SUN PHARMA
• Sun Pharmaceutical Industries Ltd gained 1 per cent after
unit Taro Pharmaceutical Industries announced the start of a
tender offer to buy back up to $200 million of its ordinary
shares.
• Sun Pharma's stake in Taro will go up to more than 69 per
cent from 66 per cent should the buyback be fully
subscribed.
• MUMBAI: The impregnable walls around top
defensive stocks such as ITC and Sun Pharma have
cracked, as they have lost nearly 10% from their October
peaks against NSE Nfity's fall of just a little over 1%. These
stocks are among the biggest losers in benchmark Nfity
during the past month.

18. • Pharma leader Sun Pharma is trading at 40 times, which is the
highest among its peers.
• Drug Controller General of India has ordered Sun
Pharmaceutical, the country's largest drug maker by m-cap, to
suspend clinical research activities at its Mumbai based bio-
analytical laboratory, a move that could slow down its regulatory
filings in India and overseas as well.
• The company has upped its revenue growth guidance to 25% for
FY14 over the previously announced range of 18-20%, but analysts
are sceptical of sustainability of margins.

19. http://www.unitedworld.edu.in/Campus
Ahmedabad Campus: Karnavati Knowledge Village,
A/907,Uvarsad, S.G.Highway, Gandhinagar
Kolkata Campus: Infinity Benchmark Tower 10th Floor, Plot -
G1, Block - EP& GP, Sec - V, Salt Lake, Kolkata.
Reg. Office: 407, Zodiac Square, 4th Floor Opp. Gurudwara, S.G.
Road, Bodakdev, Ahmedabad.